Rigel Pharmaceuticals, Inc.
RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warmā¦ read more
Healthcare
Biotechnology
25 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$37.43
Price+1.69%
$0.62
1Y
Price
Market Cap
$692.533m
Small
Price/Earnings 3y Avg5y Avg
5.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+23.3%
EBITDA Margin+14.7%
Net Profit Margin+4.6%
Free Cash Flow Margin+23.3%
EBITDA Margin+14.7%
Net Profit Margin+4.6%
Free Cash Flow MarginRevenue
$299.767m
+1.9%
1y CAGR+39.8%
3y CAGR+29.2%
5y CAGREarnings
$364.232m
-0.8%
1y CAGR+722.7%
3y CAGR+556.3%
5y CAGREPS
$18.72
-3.9%
1y CAGR+677.5%
3y CAGR+522.6%
5y CAGRBook Value
$399.897m
$504.608m
Assets$104.711m
Liabilities$45.720m
DebtDebt to Assets
9.1%
0.3x
Debt to EBITDAFree Cash Flow
$79.273m
+4.8%
1y CAGR+132.7%
3y CAGR+117.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company